First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor, AZD2014

PURPOSE: AZD2014 is a novel, oral, m-TORC 1/2 inhibitor which has shown in-vitro and in-vivo efficacy across a range of preclinical human cancer models. EXPERIMENTAL DESIGN: A rolling six dose escalation was performed to define a maximal tolerated dose (MTD) (Part A) and at MTD a further cohort of p...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Autores principales: Basu, Bristi, Dean, Emma, Puglisi, Martina, Greystoke, Alastair, Ong, Michael, Burke, Wendy, Cavallin, Maria, Bigley, Graham, Womack, Christopher, Harrington, Elizabeth A, Green, Stephen, Oelmann, Elisabeth, de Bono, Johann S, Ranson, Malcolm, Banerji, Udai
Formato: Artigo
Lenguaje:Inglês
Publicado: 2015
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4512239/
https://ncbi.nlm.nih.gov/pubmed/25805799
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2422
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares